Synthesis, Structural Characterization, and Industrial Application of beta-Methylvinyl Phosphate (MAP) in Meropenem Production

Biological Significance and Therapeutic Context

beta-Methyl vinyl phosphate is an intermediate of meropenem which is a charbapenem antibiotic with broad antibacterial spectrum, ranging from gram-positive bacteria to gram-negative bacteria, including Staphylococcus aureus, Streptococcus pneumonia, Haemophilus influenza, Klebsiella oxytaca, Enterobacter cloacae, Proteus vulgaris, etc. In addition, it can also be used as the original material in semi-synthesis of Meropenem. [1]

Structural and Crystallographic Characterization

X-ray powder diffraction data, unit-cell parameters, and space group for beta-methyl vinyl phosphate (MAP), C29H27N2O10P, are reported [a = 17.293(4) Å, b = 6.142(6) Å, c = 14.464(8) Å, α = γ = 90°, β = 112.048(0)°, unit-cell volume V = 1424.19 Å3, Z = 2, and space group P21]. All measured lines were indexed and are consistent with the P21 space group. No detectable impurity was observed. [1]

Mechanistic Advantages in Medicinal Chemistry

In the development of next-generation carbapenem antibiotics, beta-Methyl vinyl phosphate (MAP), a derivative of beta-methyl carbapenem, serves as a quintessential crystalline intermediate and an active ester scaffold. The strategic utility of MAP lies in its C-3 diphenyl phosphate moiety, which functions as a high-efficiency leaving group. This structural feature enables the facile introduction of various thiol-containing side chains via a nucleophilic displacement reaction, a process central to the industrial synthesis of Meropenem. Furthermore, the incorporation of the beta-methyl group within the MAP skeleton is critical for medicinal chemistry. It provides the necessary steric hindrance to protect the beta-lactam ring from hydrolysis by human renal dehydropeptidase-I (DHP-I). This enzymatic stability is what distinguishes Meropenem from its predecessors like Imipenem, allowing for mono-therapy applications. The study emphasizes that the crystalline nature and stability of the MAP intermediate allow for rigorous purification before the final coupling step, thereby ensuring the high stereochemical purity and overall yield of the clinical drug product. Thus, MAP remains an indispensable building block for the convergent synthesis of beta-methyl carbapenems. [2]

Optimized Industrial Synthesis Protocol

The synthesis of beta-methylvinyl phosphate (MAP), a critical crystalline intermediate for meropenem, is through a streamlined two-step protocol. The process begins with a (3S,4R)-3-[(1R)-1-hydroxyethyl]-4-[(1R)-1-methyl-3-diazo-3-(p-nitrobenzyloxycarbonyl)-2-oxopropyl] azetidin-2-one precursor, which undergoes a metal-catalyzed intramolecular cyclization. Utilizing catalysts such as rhodium(II) acetate in dichloromethane, the diazo precursor is converted into the bicyclic keto-ester core. Subsequently, a critical late-stage phosphorylation is performed by reacting this bicyclic intermediate with diphenyl chlorophosphate (DPCP) in the presence of a bulky organic base, typically N,N-diisopropylethylamine (DIPEA), under controlled low-temperature conditions. A key innovation of this method is the optimized crystallization process using a mixed solvent system of ethyl acetate and n-hexane. This purification strategy efficiently removes residual rhodium catalysts and related impurities, yielding MAP as a stable white crystalline powder with a chemical purity exceeding 99.0%. This high-purity scaffold ensures the efficient subsequent coupling of the thiol side chain, facilitating the large-scale industrial production of high-quality carbapenem antibiotics. [3]

Conversion to Meropenem

The synthesis of Meropenem is efficiently achieved through a critical nucleophilic displacement reaction utilizing beta-methylvinyl phosphate (MAP) as the key electrophilic scaffold. The process involves the coupling of high-purity crystalline MAP with the thiol-containing side chain, (2S,4S)-2-(dimethylaminocarbonyl)-4-mercaptopyrrolidine, in an organic solvent such as acetonitrile or N,N-dimethylformamide (DMF). This reaction is typically conducted under the guidance of a base like N,N-diisopropylethylamine (DIPEA) at reduced temperatures to ensure regioselectivity and prevent the degradation of the sensitive beta-lactam ring. The diphenyl phosphate group at the C-3 position of MAP acts as a superior leaving group, facilitating the formation of the carbon-sulfur bond with high stereochemical integrity. Following the coupling step, the p-nitrobenzyl (PNB) protecting groups are removed via catalytic hydrogenation, yielding Meropenem. The high purity of the MAP intermediate (above 99%) is instrumental in reducing side reactions and simplifying the final purification, thereby ensuring a high-yield industrial production of the antibiotic. [3]

References:

[1] Ma X, Tang P, Yan J, Wu X, Chen Q, Li H. X-ray powder diffraction data for beta-methyl vinyl phosphate (C29H27N2O10P). Powder Diffraction. 2015; 30(2):175-177. doi:10.1017/S088571561500007X 10.1017/S088571561500007X

[2] Gao, M. L., Kotsogianni, I., Skoulikopoulou, F., Brüchle, N. C., Innocenti, P., & Martin, N. I. (2024). Synthesis and Evaluation of Carbapenem/Metallo‐β‐Lactamase Inhibitor Conjugates. ChemMedChem, 19(21), e202400302.

[3] Zhang, G. (Inventor), & Shanghai Buddy Bio-Pharm Intermediates Ltd. (Assignee). (2011). Synthesis method of meropenem (China Patent No. CN101962383A). China National Intellectual Property Administration.

You may like